Highlights: Study indicates signal for valve degeneration in TAVI patients by eight years; Absorb now available in the USA following FDA approval; Profile of Philip Urban; Olaf Wendler & Miriam Silaschi on what is required of TAVI to become the new gold standard?
[pdfviewer width=”100%” height=”940px” beta=”true”]http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/09/CN-issue-42-EU-1.pdf[/pdfviewer]
